<DOC>
	<DOCNO>NCT02236182</DOCNO>
	<brief_summary>Study assess safety two-week administration 80 160 mcg ipratropium bromide deliver RESPIMAT® device determine 24 hour ambulatory ECG monitoring COPD patient . To assess overall safety two dos ipratropium bromide deliver RESPIMAT® device administer two-week period .</brief_summary>
	<brief_title>Study Assess Safety Ipratropium Bromide , Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>All patient must diagnosis COPD must meet follow spirometric criterion : Patients must relatively stable , moderate severe airway obstruction FEV1 &lt; =65 % predict normal FEV1 &lt; =70 % force vital capacity ( FVC ) . Predicted normal value calculate accord Morris Males : FEV1 = 0.093 ( Height inch ) 0.032 ( age ) 1.343 Females : FEV1 = 0.085 ( Height . inch ) 0.025 ( age ) 1.692 Male female patient 40 year age old Patients must smoke history 10 packyears . A packyear defined equivalent smoke one pack 20 cigarette per day year Patients must able perform pulmonary function test ( PFTs ) maintain record study period require protocol Patients must able trained proper use inhalation aerosol RESPIMAT™ device Patients must baseline electrocardiogram ( ECG ) clinical relevant arrhythmia conduction system disease ( e.g . right leave bundle branch block , second degree AV block high ) Patients must oxygen saturation &gt; =90 % &gt; =92 % record time overnight oximetry All patient must sign Informed Consent Form prior participation trial ( i.e. , least 24 hour ( h ) prior screen visit ( Visit 1 ) ) Patients clinically relevant disease COPD exclude . A clinically relevant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients recent history ( i.e . one year less ) myocardial infarction Patients recent history ( i.e . one year less ) heart failure patient past history active cardiac arrhythmia require drug therapy Patients pacemaker Patients clinically relevant abnormal baseline hematology , blood chemistry urinalysis . If abnormality defines disease list exclusion criterion patient exclude All patient serum glutamic oxaloacetic transaminase / Aspartate aminotransferase ( SGOT/AST ) &gt; 80 IU/L , serum glutamic pyruvic transaminase / Alanine transaminase ( SGPT/ALT ) &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dl , creatinine &gt; 2.0 mg/dl exclude regardless clinical condition . Repeat laboratory evaluation conduct subject Patients blood eosinophil count &gt; =600/mm3 . A Repeat eosinophil count conduct patient Patients history cancer , treat basal cell carcinoma , within last 5 year Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 Patients history asthma , allergic rhinitis atopy Patients history and/or active alcohol drug abuse Patients know active tuberculosis Patients upper respiratory tract infection COPD exacerbation past 6 week prior screen visit ( Visit 1 ) baseline period Patients know symptomatic prostatic hypertrophy bladder neck obstruction Patients know narrowangle glaucoma Patients current significant psychiatric disorder Patients regular use daytime oxygen therapy Patients treat cromolyn sodium nedocromil sodium Patients treat antihistamines Patients use oral corticosteroid medication unstable dos ( i.e . le six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day Patients treat betablocker medication Patients change therapeutic plan within last six week prior screen visit ( visit 1 ) Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( e.g. , oral contraceptive , intrauterine device , diaphragm Norplant® ) Patients know hypersensitivity ant cholinergic drug component ATROVENT® RESPIMAT™ solution include bacteriostatic agent benzalkonium chlorid ( BAC ) edetic acid ( EDTA ) Patients take investigational drug within 1 month 6 halflives ( whichever longer ) prior screen visit ( visit1 ) Previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>